This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE-BR, their first commercialized test for breast cancer. The document also summarizes Biocept's growth strategy, which includes expanding their test menu, improving operational efficiency, and increasing market penetration. It introduces Biocept's executive team and describes their extensive experience in cancer diagnostics, genomics, and life sciences.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
Cancer Genetics, Inc. is a personalized cancer diagnostics company that provides genomic testing services and proprietary diagnostic products. They have 5 commercially available diagnostic products that classify cancers like leukemia, lymphoma, kidney cancer, cervical cancer, and endometrial cancer. Their business model includes proprietary products, clinical cancer testing services, and clinical trial services. They aim to personalize cancer treatment by using biomarkers and genomic analysis to improve diagnosis, prognosis, and therapeutic selection compared to traditional methods.
This company presentation provides an overview of a cancer genetic testing services company. Key points include:
- The company has experienced strong and consistent growth in revenue and test volume over the past 10 years through both organic growth and acquisitions.
- It provides a broad menu of genetic and molecular testing services including next generation sequencing and is developing liquid biopsy tests.
- The company has an experienced management team with experience in large reference laboratories. It is focused on innovation, cost management, and expanding its commercial footprint.
- Financial results show increasing margins, productivity, and adjusted EBITDA despite lower average prices per test, demonstrating strong operating leverage as the business scales.
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Exact Sciences
This document discusses Exact Sciences' Cologuard home screening test for colorectal cancer. It summarizes early results from the launch, including that the number of physicians ordering and patients using Cologuard is growing rapidly. Over 13,000 physicians have ordered Cologuard already. The document also outlines strategies to further expand adoption, including securing insurance coverage, influencing medical guidelines, and activating patients. The goal is to screen millions more Americans for colorectal cancer.
- NeoGenomics is a pure-play cancer genetics testing company that has experienced fast revenue and test volume growth through expanding its test menu and increasing sales force productivity. Its "tech-only" business model focuses on partnerships with oncologists and hospitals to provide genetic testing services.
- The company has consistently grown its annual revenue and tests performed historically through new test innovations, a growing sales force, and greater productivity. It is targeting further market share gains and operating leverage to accelerate cash flow and earnings growth.
NeoGenomics provides cancer genetic testing services to oncologists, pathologists, and hospitals. It has experienced strong and consistent growth in revenue and tests performed annually through expanding its test menu, increasing sales force productivity, and gaining market share. The company aims to continue its growth by launching new tests, pursuing partnerships and acquisitions, and capitalizing on the large and growing market for cancer genetic testing fueled by an aging population and advancements in targeted therapies.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
Cancer Genetics, Inc. is a personalized cancer diagnostics company that provides genomic testing services and proprietary diagnostic products. They have 5 commercially available diagnostic products that classify cancers like leukemia, lymphoma, kidney cancer, cervical cancer, and endometrial cancer. Their business model includes proprietary products, clinical cancer testing services, and clinical trial services. They aim to personalize cancer treatment by using biomarkers and genomic analysis to improve diagnosis, prognosis, and therapeutic selection compared to traditional methods.
This company presentation provides an overview of a cancer genetic testing services company. Key points include:
- The company has experienced strong and consistent growth in revenue and test volume over the past 10 years through both organic growth and acquisitions.
- It provides a broad menu of genetic and molecular testing services including next generation sequencing and is developing liquid biopsy tests.
- The company has an experienced management team with experience in large reference laboratories. It is focused on innovation, cost management, and expanding its commercial footprint.
- Financial results show increasing margins, productivity, and adjusted EBITDA despite lower average prices per test, demonstrating strong operating leverage as the business scales.
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Exact Sciences
This document discusses Exact Sciences' Cologuard home screening test for colorectal cancer. It summarizes early results from the launch, including that the number of physicians ordering and patients using Cologuard is growing rapidly. Over 13,000 physicians have ordered Cologuard already. The document also outlines strategies to further expand adoption, including securing insurance coverage, influencing medical guidelines, and activating patients. The goal is to screen millions more Americans for colorectal cancer.
- NeoGenomics is a pure-play cancer genetics testing company that has experienced fast revenue and test volume growth through expanding its test menu and increasing sales force productivity. Its "tech-only" business model focuses on partnerships with oncologists and hospitals to provide genetic testing services.
- The company has consistently grown its annual revenue and tests performed historically through new test innovations, a growing sales force, and greater productivity. It is targeting further market share gains and operating leverage to accelerate cash flow and earnings growth.
NeoGenomics provides cancer genetic testing services to oncologists, pathologists, and hospitals. It has experienced strong and consistent growth in revenue and tests performed annually through expanding its test menu, increasing sales force productivity, and gaining market share. The company aims to continue its growth by launching new tests, pursuing partnerships and acquisitions, and capitalizing on the large and growing market for cancer genetic testing fueled by an aging population and advancements in targeted therapies.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
This presentation provides an overview of NeoGenomics' proposed acquisition of Clarient, which would more than double NeoGenomics' revenue. The strategic rationale is that the combined company would have greater scale and a more balanced oncology product portfolio, allowing it to be a lower-cost provider. It would also gain a larger clinical trials business and enhanced geographic coverage. Synergies of $20-30 million annually are projected from consolidating laboratories, purchasing, cross-selling and other areas. The acquisition supports NeoGenomics' strategy of using M&A to accelerate its vision of becoming a leading cancer testing and information company.
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
This document provides an overview of Cancer Genetics, Inc.'s presentation at the RedChip Global Conference on October 15, 2014. The presentation discusses CGI's business focus on developing genomic tests to assess and personalize cancer treatment. It highlights six proprietary diagnostic products that have been commercially launched, as well as CGI's product pipeline. The presentation also summarizes CGI's partnerships with academic and research institutions and its global operations across multiple locations.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
The investor presentation discusses Cancer Genetics, Inc., a company that provides genomic testing services. It highlights the company's recent growth, including acquisitions, research collaborations, product launches, and patents. The presentation also outlines the company's targeted NGS panel pipeline for diseases like multiple myeloma, CLL, and myeloid cancers. It positions Cancer Genetics as a leader in oncology diagnostics with proprietary tests that can help guide cancer diagnosis, prognosis, and treatment selection.
Cologuard is a non-invasive stool DNA test that is more effective and has higher patient compliance than other colon cancer screening options. It has received FDA approval and Medicare coverage, addressing a large underserved screening market. Exact Sciences is expanding insurance coverage and physician adoption of Cologuard to increase screening rates and detect more curable-stage cancers. First quarter 2016 revenue was $14.8 million as adoption grows.
This investor presentation by Cancer Genetics, Inc provides an overview of the company and its proprietary genomic testing programs. CGI has locations in the US, India, and China serving biopharma, clinical, and research clients. It has launched 7 proprietary diagnostic products focused on hematologic and urogenital cancers, and is working to validate additional next generation sequencing panels. CGI's tests provide information to aid in diagnosis, prognosis, and therapeutic decision making for cancers like CLL, cervical cancer, and kidney cancer. The company is collaborating with academic centers to further develop and validate its genomic tests.
This document provides an overview of Cancer Genetics, Inc. It discusses the company's focus on empowering personalized cancer treatment through molecular diagnostics. The summary highlights Cancer Genetics' proprietary diagnostic products for various cancers, partnerships with biopharma companies, growth in revenue and testing volume in 2013, and pipeline of diagnostic tests in development. It also outlines the company's business model and strategy to commercialize its products to target markets globally.
This corporate presentation discusses the company's mission to help eradicate colon cancer. It summarizes the challenges of colon cancer as the second deadliest cancer in the U.S. and highlights Cologuard, the company's non-invasive stool DNA test, as a way to address low screening rates and detect precancerous polyps. Data shows Cologuard has strong performance in detecting cancer and precancer, and its inclusion in guidelines is expected to help make it the standard of care for colon cancer screening.
This document provides an agenda and background information for an Investor & Analyst Day event being held by Exact Sciences. The event will include presentations on Exact Sciences' vision to become a leading cancer screening company, an overview of their Cologuard test and commercialization efforts, and their pipeline of new screening tests in development for cancers like pancreatic, lung and esophageal cancer. Attendees will also have the option to tour Exact Sciences' laboratories and customer care center after the presentations.
Kevin Conroy, CEO of Exact Sciences, presented at the 36th Annual J.P. Morgan Healthcare Conference. He discussed Exact Sciences' vision of helping win the war on cancer through early detection using Cologuard. Cologuard demand continues to grow, with over 900,000 people screened and 4,300 early-stage cancers detected since launch. Exact Sciences reported preliminary unaudited Q4 2017 revenue of $86.9-$87.9 million and full year revenue of $265.5-$266.5 million, representing strong year-over-year growth. Exact Sciences is also investing in expanding infrastructure, marketing, and its product pipeline to pursue a multi-billion dollar market opportunity in col
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
The document discusses Cancer Genetics' focus on personalized cancer treatment through genomics. It provides an overview of Cancer Genetics' business model, which utilizes molecular diagnostic testing to support the cancer care continuum and improve outcomes. Key acquisitions are highlighted that expand Cancer Genetics' capabilities in clinical services, research, and pharmacogenomics.
This document discusses Ruthigen, Inc., a drug development company focused on developing RUT58-60, a hypochlorous acid-based drug candidate for invasive use. RUT58-60 aims to improve patient outcomes for invasive procedures by reducing post-surgical infections in a more effective way than current standard of care antibiotics. Published studies on Microcyn, another hypochlorous acid-based product, show promise in reducing infection rates for diabetic foot ulcers and coronary artery bypass graft surgery wounds. If successful, RUT58-60 could help hospitals reduce costs by shortening patient stays and lowering readmission rates for post-surgical infections.
The presentation summarizes Clean Coal Technologies' business and technology. It discusses the company's management team and strategic partnerships. It then provides an overview of the growing global demand for coal and issues with existing coal, before detailing CCTI's patented coal upgrading processes. The presentation outlines the technology, its benefits over alternatives, the planned commercial rollout and compelling projected plant economics.
This document provides an overview of Vaccinogen and its cancer vaccine OncoVAX. OncoVAX is designed to reduce the risk of cancer recurrence after surgery and has shown statistically significant results in reducing recurrence in phase 3 trials for stage 2 colon cancer. Vaccinogen has completed 5 clinical studies involving over 750 patients and is in the final stages of clinical development. OncoVAX represents a potential $5 billion market opportunity in the US and Europe for treating colon and other cancers. The manufacturing process for OncoVAX is straightforward and scalable.
This presentation provides an overview of NeoGenomics' proposed acquisition of Clarient, which would more than double NeoGenomics' revenue. The strategic rationale is that the combined company would have greater scale and a more balanced oncology product portfolio, allowing it to be a lower-cost provider. It would also gain a larger clinical trials business and enhanced geographic coverage. Synergies of $20-30 million annually are projected from consolidating laboratories, purchasing, cross-selling and other areas. The acquisition supports NeoGenomics' strategy of using M&A to accelerate its vision of becoming a leading cancer testing and information company.
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
This document provides an overview of Cancer Genetics, Inc.'s presentation at the RedChip Global Conference on October 15, 2014. The presentation discusses CGI's business focus on developing genomic tests to assess and personalize cancer treatment. It highlights six proprietary diagnostic products that have been commercially launched, as well as CGI's product pipeline. The presentation also summarizes CGI's partnerships with academic and research institutions and its global operations across multiple locations.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
The investor presentation discusses Cancer Genetics, Inc., a company that provides genomic testing services. It highlights the company's recent growth, including acquisitions, research collaborations, product launches, and patents. The presentation also outlines the company's targeted NGS panel pipeline for diseases like multiple myeloma, CLL, and myeloid cancers. It positions Cancer Genetics as a leader in oncology diagnostics with proprietary tests that can help guide cancer diagnosis, prognosis, and treatment selection.
Cologuard is a non-invasive stool DNA test that is more effective and has higher patient compliance than other colon cancer screening options. It has received FDA approval and Medicare coverage, addressing a large underserved screening market. Exact Sciences is expanding insurance coverage and physician adoption of Cologuard to increase screening rates and detect more curable-stage cancers. First quarter 2016 revenue was $14.8 million as adoption grows.
This investor presentation by Cancer Genetics, Inc provides an overview of the company and its proprietary genomic testing programs. CGI has locations in the US, India, and China serving biopharma, clinical, and research clients. It has launched 7 proprietary diagnostic products focused on hematologic and urogenital cancers, and is working to validate additional next generation sequencing panels. CGI's tests provide information to aid in diagnosis, prognosis, and therapeutic decision making for cancers like CLL, cervical cancer, and kidney cancer. The company is collaborating with academic centers to further develop and validate its genomic tests.
This document provides an overview of Cancer Genetics, Inc. It discusses the company's focus on empowering personalized cancer treatment through molecular diagnostics. The summary highlights Cancer Genetics' proprietary diagnostic products for various cancers, partnerships with biopharma companies, growth in revenue and testing volume in 2013, and pipeline of diagnostic tests in development. It also outlines the company's business model and strategy to commercialize its products to target markets globally.
This corporate presentation discusses the company's mission to help eradicate colon cancer. It summarizes the challenges of colon cancer as the second deadliest cancer in the U.S. and highlights Cologuard, the company's non-invasive stool DNA test, as a way to address low screening rates and detect precancerous polyps. Data shows Cologuard has strong performance in detecting cancer and precancer, and its inclusion in guidelines is expected to help make it the standard of care for colon cancer screening.
This document provides an agenda and background information for an Investor & Analyst Day event being held by Exact Sciences. The event will include presentations on Exact Sciences' vision to become a leading cancer screening company, an overview of their Cologuard test and commercialization efforts, and their pipeline of new screening tests in development for cancers like pancreatic, lung and esophageal cancer. Attendees will also have the option to tour Exact Sciences' laboratories and customer care center after the presentations.
Kevin Conroy, CEO of Exact Sciences, presented at the 36th Annual J.P. Morgan Healthcare Conference. He discussed Exact Sciences' vision of helping win the war on cancer through early detection using Cologuard. Cologuard demand continues to grow, with over 900,000 people screened and 4,300 early-stage cancers detected since launch. Exact Sciences reported preliminary unaudited Q4 2017 revenue of $86.9-$87.9 million and full year revenue of $265.5-$266.5 million, representing strong year-over-year growth. Exact Sciences is also investing in expanding infrastructure, marketing, and its product pipeline to pursue a multi-billion dollar market opportunity in col
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
The document discusses Cancer Genetics' focus on personalized cancer treatment through genomics. It provides an overview of Cancer Genetics' business model, which utilizes molecular diagnostic testing to support the cancer care continuum and improve outcomes. Key acquisitions are highlighted that expand Cancer Genetics' capabilities in clinical services, research, and pharmacogenomics.
This document discusses Ruthigen, Inc., a drug development company focused on developing RUT58-60, a hypochlorous acid-based drug candidate for invasive use. RUT58-60 aims to improve patient outcomes for invasive procedures by reducing post-surgical infections in a more effective way than current standard of care antibiotics. Published studies on Microcyn, another hypochlorous acid-based product, show promise in reducing infection rates for diabetic foot ulcers and coronary artery bypass graft surgery wounds. If successful, RUT58-60 could help hospitals reduce costs by shortening patient stays and lowering readmission rates for post-surgical infections.
The presentation summarizes Clean Coal Technologies' business and technology. It discusses the company's management team and strategic partnerships. It then provides an overview of the growing global demand for coal and issues with existing coal, before detailing CCTI's patented coal upgrading processes. The presentation outlines the technology, its benefits over alternatives, the planned commercial rollout and compelling projected plant economics.
This document provides an overview of Vaccinogen and its cancer vaccine OncoVAX. OncoVAX is designed to reduce the risk of cancer recurrence after surgery and has shown statistically significant results in reducing recurrence in phase 3 trials for stage 2 colon cancer. Vaccinogen has completed 5 clinical studies involving over 750 patients and is in the final stages of clinical development. OncoVAX represents a potential $5 billion market opportunity in the US and Europe for treating colon and other cancers. The manufacturing process for OncoVAX is straightforward and scalable.
Energy Fuels is a uranium mining and milling company with operations in the United States. It currently produces 500,000 pounds of uranium per year and has the goal of increasing production to over 5 million pounds annually as market conditions improve. Energy Fuels owns numerous uranium projects throughout the Western U.S. and operates the only conventional uranium mill in the country. The company is pursuing a strategy of low-cost production while conserving capital and maintaining production optionality for the future.
The document discusses accounts payable (AP) transformation and how moving from a paper-based to digital process can provide benefits. It outlines common problems with paper-based AP like high costs and lack of visibility. The solution presented is an end-to-end AP automation platform that handles invoice receipt, approval workflows, payments and spend management. Key benefits highlighted include lower processing costs, improved staff efficiency, and enhanced supplier relationships.
Hangw/ is a global, mobile social media platform that allows users to connect and share live video broadcasts. It has grown rapidly since launch, with over 250,000 downloads and millions of user sessions. The platform generates revenue by showing ads before, during, and after live broadcasts, and shares a portion of ad dollars with broadcasters. Celebrities, athletes, and other influencers use Hangw/ to interact directly with their fans.
This document discusses Genius Brands International and its business model of providing children's entertainment content across multiple platforms. It notes that animated content has enduring appeal across generations and borders. It highlights Genius Brands' existing properties like Baby Genius which have had success on television and other platforms. The document outlines Genius Brands' plans to expand these properties to new distribution channels internationally and through new merchandise programs. It also presents several new animated series concepts in development. Biographies of the Chairman and CEO Andy Heyward and another executive emphasize their experience in children's entertainment.
Lattice Inc. provides technology services to correctional facilities and has experienced 700% revenue growth from 2009 to 2013. It offers a suite of cloud-based services that provide secure communications and information technology to smaller facilities. Some of its products and services include video visitation, email, music downloads, and an integrated jail management software solution. While it faces competition from larger national service providers, Lattice has a unique technology advantage in both the US and foreign markets it is expanding into. Its integrated corrections operations network platform provides cost reductions and enhanced revenue streams for facilities.
Oragenics is developing novel antibiotics and probiotics through synthetic biology collaborations. For antibiotics, they are focusing on lantibiotics, a class of naturally produced antibacterial peptides, with a lead compound called MU1140 showing promise against MRSA, VRE and C. difficile. For probiotics, they are engineering bacteria to produce and deliver therapeutics locally for oral diseases. Their OTC probiotic product ProBiora3 supports oral health currently. Upcoming milestones include animal studies on MU1140 in 2014 and generating genetically modified probiotic prototypes in 2014-2015.
This document discusses forward-looking statements and risks for Akers Biosciences, Inc. It notes that any statements regarding future financial performance, development of products and services, or opportunities should be considered forward-looking. Actual results may differ due to risks in development, clinical trials, need for capital, and intellectual property maintenance. The document also provides brief biographies of ABI's experienced management team and board.
Exeo Entertainment, Inc. is a manufacturing company concentrating on developing innovative products that fill a clearly defined need in today’s interactive entertainment industry. Featured products include the Zaaz™ smart TV keyboards, Patented Psyko Krypton™ 5.1 gaming headphones, Krankz Bluetooth music headphones, an Android® based portable gaming system, and the Extreme Gamer® -the world’s first multi–disc game changer.
- Bitcoin Shop is one of the first publicly traded companies focused on the virtual currency ecosystem. It operates an ecommerce platform that accepts bitcoin and other cryptocurrencies as payment.
- The company is developing its BTCS 2.0 platform to expand its product offerings and vendor base. It aims to build a virtual currency ecosystem through ecommerce.
- Bitcoin Shop has a experienced management team with expertise in capital markets, technology, and the virtual currency industry. It plans to grow its customer base and monetize through additional service offerings.
This document contains forward-looking statements and disclaimers about InterCloud's financial projections and business strategies. It notes that actual results could differ from what is presented due to various risk factors. It also states that the pro forma financial information provided is constructed from separate financial statements of the companies involved and does not necessarily represent what the combined financials would be. The document provides an overview of InterCloud, describing its cloud platforms and services, growth strategies, key metrics like revenue and EBITDA, value propositions for investors and customers, examples of professional services case studies, comparative financial statements, and backgrounds of the key executives.
Profire Energy is an oilfield technology company that specializes in burner management systems (BMS). [1] It was founded in 2002 in Alberta, Canada and is now headquartered in Utah with operations throughout North America and Brazil. [2] BMS automate combustion processes, improving safety and efficiency for oil and gas companies by quickly reigniting burner flames when failures occur. [3] While the market for BMS is large due to over 1.3 million oil and gas wells in North America, it remains served by only a few companies. Profire Energy seeks to expand its product offerings and distribution network to capture more of this growing market.
Digiplex is a growing movie theater circuit focused on acquiring and improving theaters. It currently owns 19 theaters with 184 screens across 6 states. Digiplex aims to grow its footprint to 100 theaters and 1,000 screens located primarily in top markets. The company pursues an acquisition strategy of purchasing cash flow positive theaters at reasonable multiples. It also seeks to increase theater utilization and revenue through alternative programming events. Digiplex is led by an experienced management team with deep industry expertise.
Srne sorrento therapeutics-redchip conference presentation (20140123)-reducedRedChip Companies, Inc.
Sorrento Therapeutics presents its next-generation cancer therapeutics pipeline, including Cynviloq and RTX. Cynviloq is a late-stage paclitaxel product that offers potential advantages over Taxol and Abraxane such as higher dosing. It has demonstrated efficacy in multiple Phase 2 trials and is pursuing an abbreviated regulatory pathway for approval. RTX is a clinical stage non-opiate pain treatment that produces long-lasting analgesia through a single injection by targeting TRPV1 receptors. Sorrento aims to develop multiple products from RTX through intrathecal and intraganglionic injections.
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
This document provides an overview of Big North Graphite Corp., a mining company exploring graphite opportunities in Mexico and Canada. It summarizes the management team's experience, the capital structure including shares outstanding and warrants, and key investment highlights. Specifically, it notes Big North is currently selling amorphous graphite in Mexico and aims to restart near-term flake graphite production at its recently acquired El Tejon Flake Graphite Mine and Mill in Oaxaca, Mexico, which was previously operational until 2002. A cautionary note also indicates forward-looking statements may materially differ from expectations.
AV Therapeutics is developing new cancer therapeutics including Capridine, a patented drug that has shown specific activity against prostate cancer in preclinical studies. Capridine addresses an unmet need as it has limited side effects and bone toxicity compared to existing treatments. AV Therapeutics plans to submit an IND application to begin Phase I/II clinical trials for Capridine based on its promising preclinical results showing potency against prostate cancer cells and taxane resistant cell lines with no toxicity to bone marrow cells. The company has a strong management team and scientific advisory board from top institutions to advance its pipeline of safer and more effective cancer treatments.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
This company presentation provides an overview of NeoGenomics and their cancer genetic testing services. Some key points:
- NeoGenomics is a fast-growing cancer genetics lab that services oncologists, pathologists, and hospitals through strategic partnerships and a tech-only model.
- They have an experienced management team with experience at large cap labs and offer the most comprehensive cancer testing menu in the industry.
- NeoGenomics has demonstrated a proven track record of consistent growth over the last 10 years with 65% CAGR in revenue and test volume.
- Their focus for 2015 includes expanding next generation sequencing, developing a prostate cancer liquid biopsy test, launching new products, and growing their clinical trials business
This document provides an overview of Cancer Genetics, Inc. (CGI) and their focus on being an oncology diagnostics partner from bench to bedside. Some key points:
- CGI utilizes targeted acquisitions and collaborations with research institutions to expand their testing capabilities and global footprint.
- They have a proprietary portfolio of over 20 genomic tests and panels focused on cancers like blood cancers, lymphomas, lung cancer, and solid tumors.
- CGI partners with leading biopharma companies, supporting over 120 clinical trials with testing and services. They have contracts with 8 of the top 10 biopharma companies.
Liquid Biopsy: From Isolation to Downstream Applications 2018 Report by Yole ...Yole Developpement
How will liquid biopsy change cancer care?
More information on: https://www.i-micronews.com/category-listing/product/liquid-biopsy-from-isolation-to-downstream-applications-2018.html
Cancer Genetics provides personalized cancer treatment through molecular diagnostic testing. They have launched 6 proprietary diagnostic products targeting hematological and urogenital cancers. Their tests help determine cancer type and prognosis, guiding treatment selection. Recent acquisitions expand their capabilities and access to new markets in India. Their business model provides clinical testing services to oncologists and biopharma partnerships to support drug development.
The document provides an overview of Exact Sciences and its colorectal cancer screening test Cologuard. It discusses Cologuard's performance in clinical trials, cost-effectiveness, growing adoption rates, and commercial strategy to increase screening rates in the US. Exact Sciences expects over 240,000 Cologuard tests to be completed in 2016, up from 104,000 in 2015, and revenue is forecasted to be between $90-100 million.
- IDXG provides molecular diagnostic tests for cancer risk assessment and prognosis.
- Recent accomplishments include new product launches, reimbursement from Aetna for ThyraMir, and achieving approval in New York State.
- The presentation provides financial information, with revenue growing but losses continuing from investments in sales, R&D and administrative expenses.
The document discusses liquid biopsies and next generation cancer molecular diagnostics. It summarizes that OncoCyte Corporation is focused on developing diagnostic tests for early cancer detection using liquid biopsies, with an initial focus on tests for lung cancer. Key points include that lung cancer diagnostics represents a large market opportunity and that OncoCyte's preliminary lung cancer diagnostic test shows strong performance in clinical trials with high sensitivity and specificity. The test has the potential to reduce risky follow-up procedures for patients and provide significant healthcare cost savings.
The document provides an overview of Genetic Technologies Company (GTG), including:
- GTG is developing genetic risk assessment products to prevent disease morbidity and mortality.
- GTG has 20 years experience commercializing genomics products and research partnerships with universities and companies.
- GTG's flagship product BREVAGenplus predicts a woman's risk of developing breast cancer using a cheek swab and has been clinically validated in multiple populations.
September 2016-corporate-presentation-finalExact Sciences
The document is a corporate presentation from Exact Sciences that discusses:
1) Cologuard, a non-invasive stool DNA screening test for colorectal cancer that is FDA approved and gaining insurance coverage.
2) Exact Sciences' strategy to increase adoption of Cologuard through physician and patient education, national marketing campaigns, and expanding insurance reimbursement.
3) Progress made in 2016, including growing test volumes, revenue guidance of $90-100 million for the year, and a cash balance of $224.1 million as of the second quarter.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Exact Sciences Corporate Presentation: April 2016Exact Sciences
The corporate presentation discusses colon cancer as the second deadliest cancer in the United States and highlights the need for improved screening rates. It summarizes the performance of Cologuard, Exact Sciences' non-invasive stool DNA screening test, including superior cancer detection rates compared to other screening methods based on clinical trials and studies. The presentation outlines Exact Sciences' commercial strategy to increase awareness of Cologuard among physicians, payers, and patients with the goal of driving compliance and access to colon cancer screening.
This presentation provides an overview of the company and its acquisition of Clarient. It summarizes that the acquisition will more than double the company's revenue and more than triple its adjusted EBITDA. The acquisition provides key benefits like synergies of $20-30 million annually within 3-5 years, a combined leadership in cancer testing, and expanded geographic coverage across the United States with field sales representatives.
Exact Sciences chairman and CEO Kevin Conroy delivered the company's presentation at the 2015 Baird 2015 Healthcare Conference in New York at 9:40 a.m. ET on Wednesday, Sept. 9.
An archive of the webcast is available here: http://wsw.com/webcast/baird43/register.aspx?conf=baird43&page=exas&url=http://wsw.com/webcast/baird43/exas/index.aspx
This corporate presentation discusses Exact Sciences' non-invasive colon cancer screening test, Cologuard. It summarizes key points about colon cancer as the second deadliest cancer in the U.S. and highlights Cologuard's superior performance in detecting cancer and precancer compared to other screening options based on clinical trial results. The presentation also provides an overview of Exact Sciences' commercial strategy and growth plan to increase awareness and adoption of Cologuard for colon cancer screening.
Exact Sciences Corporate Presentation: June 2016Exact Sciences
- The corporate presentation provides an overview of the company's mission to help eradicate colon cancer through partnerships with various stakeholders. It highlights key facts about colon cancer incidence and mortality rates.
- Cologuard, the company's non-invasive stool DNA screening test, is described as addressing the colon cancer challenge through multi-target screening with high sensitivity and specificity rates confirmed in clinical studies.
- The presentation outlines the large market opportunity for Cologuard given the underutilized colon cancer screening rates in the US and Cologuard's inclusion in medical guidelines and recommendations.
MDxHealth provides molecular diagnostic tests to improve diagnosis and treatment decisions for urological cancers like prostate and bladder cancer. Their lead product is ConfirmMDx, which helps determine if a repeat biopsy is needed after an initial negative biopsy result. They are also launching SelectMDx, a urine-based test to improve patient selection for initial biopsies. Looking forward, they plan to expand their product portfolio and commercial footprint in the US and EU to address unmet needs in urological cancer testing and help reduce unnecessary invasive procedures.
- NeoGenomics is acquiring Clarient, which should more than double NeoGenomics' revenue in 2016.
- The acquisition creates a leading cancer testing and information company with expanded geographic coverage and a more comprehensive product menu.
- Synergies of $20-30 million per year are expected from cost savings and cross-selling opportunities between the two companies.
This presentation provides an overview of the company and its recent acquisition of Clarient. It summarizes that the acquisition is expected to more than double the company's revenue and more than triple its adjusted EBITDA in 2016. The company operates a fast-growing cancer genetics laboratory and sees significant opportunity in consolidating the dynamic and consolidating industry. The acquisition combines the companies' complementary assets and geographic footprints to create a leader in hematological and solid tumor cancer testing with synergies of $20-30 million annually.
“The Coin Tree is a cloud-based storage, insurance, and payment processing platform for bitcoin that leverages cutting edge transactional security to serve the ever expanding virtual currency community."
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment aims to be a theatrical motion picture production and financing company focused on producing edgy, high quality films with strong casts and lean budgets. It mitigates risk through fiscal precision by financing projects once they are fully developed and ready to produce, offering investors a quicker return. Recent successful films include Lee Daniels' The Butler, Life of Crime, and Life After Beth.
InterCloud Systems provides cloud-centric solutions and services to enterprises and service providers. Their two main business focus areas are Software Defined Enterprise and Cloud to Cloud Mobility. They help customers modernize infrastructure, develop cloud strategies, and deliver cloud-centric IT visions aligned to business value. InterCloud partners with major cloud platform and solution providers like VMware, OpenStack, and CloudStack.
This presentation provides an overview of SANUWAVE Health Inc., a regenerative medicine company developing non-invasive biological response activation devices. SANUWAVE's lead product, dermaPACE, is in a Phase III FDA trial for treating diabetic foot ulcers and has the potential for approval in 2015 pending positive results. DermaPACE offers a lower-cost, non-invasive alternative to existing wound therapies. If approved, dermaPACE could address the large diabetic foot ulcer market and be expanded to other applications. SANUWAVE completed a $9.3 million capital raise to fund the dermaPACE trial and has 38 patents covering its shockwave technology platform.
Genius Brands International is a company focused on providing children's entertainment content with purpose for toddlers to tweens. It was created through the merger of A Squared Entertainment and Genius Brands. The document discusses Genius Brands' plans to grow its portfolio of animated properties like Baby Genius, Warren Buffett's Secret Millionaires Club, and new shows in partnership with Stan Lee and Martha Stewart. It aims to distribute this content across television, online, mobile and through a new streaming service, while supporting the content through consumer products licensing. The management team, including Andy and Amy Heyward, have decades of experience in the children's entertainment industry.
StationDigital is a digital media and ecommerce platform that allows users to stream or access any media and purchase digital and physical goods from any device. It has grown rapidly since its public beta launch in 2013, achieving over 1.3 million mobile users. The presentation outlines StationDigital's mission and growth strategy, competitive advantages over other media companies, and large market opportunity in digital media and ecommerce. It argues that StationDigital is well positioned for continued growth and market share capture.
DRONE Aviation Corp (DRNE) was formed in April 2014 to penetrate the rapidly growing Unmanned Aerial Systems (UAS) business in U.S. and abroad for government and commercial customers.
DRNE’s mission is to aggressively penetrate the expanding Drone market with our unique Tethered Drones, which are currently being fielded to the U.S. Department of Defense and State and Local municipalities.
DRNE owns and operates Florida-based Lighter Than Air Systems Corp (LTAS), a developer and supplier of unique and specialized aerial solutions to the U.S. Government, State municipalities, and commercial entities.
InterCloud Systems Incorporated is a single - source provider of end - to - end IT technology and telecom solutions to the ent erprise, service provider, and g overnment markets through “Cloud Platforms” and professional services. “Cloud Comput ing”, is defined as the use of computing resources (compute, NTK, Storage) that are delivered as a managed service over a network. InterCloud offers its service provider custo mers the ability to utilize “cloud” solutions inside their existing network footp rint as well as in a “white label environment” so it can offer a suite of cloud products under their own brand, delivered over the broadband services it presently sell s . ICLD’s cloud services include infrastructure as a service (IaaS), platform as a servi ce (PaaS), and software as a service (SaaS) .
This document provides an overview of Actinium Pharmaceuticals, Inc. and summarizes their proprietary alpha particle immunotherapy technology and product pipeline. Key points include:
1) Actinium has a pipeline of targeted radiotherapy candidates using alpha emitters to treat various blood cancers. Their lead candidate, Iomab-B, is being developed for conditioning blood cancer patients prior to bone marrow transplant.
2) Iomab-B has shown promising results in clinical trials, successfully preparing older refractory AML patients for transplant who otherwise would not be eligible. Actinium has FDA agreement to advance Iomab-B into a Phase III registration trial.
3) Actinium has a proprietary technology
The nuclear energy industry has lain stagnant for over 30 years and has suffered from missteps and perception issues.
Lightbridge is here to innovate and change the conversation. About: Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge's breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.
Richfield Oil & Gas Company (OTCQX: ROIL) is an independent exploration and production company headquartered in Salt Lake City, Utah. The Company’s current oil production flows from wells in fields located in Kansas and Wyoming. In addition to several thousand acres in Kansas, Richfield also owns strategically-located exploratory leases in central Utah on trend to major oil discoveries.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
American Water provides water and wastewater services to approximately 14 million people in 16 states, has a market capitalization of $8.6 billion, and seeks to continue growing its regulated water business through capital investments and acquisitions while also expanding its complementary market-based business lines. The company has delivered strong total shareholder returns since its 2008 IPO and maintains a transparent dividend policy aimed at increasing its dividend in line with normalized earnings per share growth.
Direct Insite (“DIRI”) provides cloud-based, ERP-agnostic solutions that automate Accounts Payable (AP) and Accounts Receivable (AR) invoice processes for Global 3000 companies. Their solutions include invoice validation, order matching, consolidation, dispute handling and e-payment processing. DIRI helps clients eliminate manual processes and costs associated with doing everything on paper. By migrating from paper to electronic, DIRI can reduce transactions costs 50-70% and reduce time by 80%. Current clients include Siemens, HP, IBM, Saint-Gobain, Shell Oil, and Hyatt with a Global vendor network of 350,000+ suppliers.
Lattice Incorporated (“Lattice” or the “Company”), founded in 1973, provides secure communications and information technology, specializing in deploying advanced technology and services to create innovative, cost - effective solutions for the Company’s global customers. The Company provides both wholesale and direct services to correctional facilities and their service providers in the U.S., Canada and Europe. Expansion of Lattice’s direct and wholesale services, including increased techno logy equipment and software sales to wholesale customers, is expected to drive revenue growth and increased margins in the quarters ahead
Quadrant 4 Systems Corporation is a leading provider in of health exchange platforms, innovative software products and proprietary SMAC (social media, mobility, analytics and cloud computing) solutions to enterprise clients in Retail and Manufacturing, Media and Publishing, Financial Services and Health Care sectors.
Energy Fuels is the nation's leading conventional uranium producer, supplying approximately 25% of the uranium produced in the U.S. (based on FY-2013 deliveries). The Company also has the capability to be a significant producer of vanadium. Energy Fuels owns and operates the White Mesa Mill, which is the only conventional uranium mill currently operating in the U.S. The mill is capable of processing 2,000 tons per day of uranium ore and producing up to 8 million lbs. of U3O8 per year (depending on ore grade).
This document provides a safe harbor statement and background information on VeriTeQ Corporation. It discusses forward-looking statements and risks associated with investment. It then provides an overview of the company, including its founding, acquisitions, regulatory clearances, and financing activities. Key areas of focus for the company are discussed, including medical device UDI/identification and biosensing/radiation dosimetry technologies. Leadership and intellectual property are also summarized.
Understanding Catalytic Converter Theft:
What is a Catalytic Converter?: Learn about the function of catalytic converters in vehicles and why they are targeted by thieves.
Why are They Stolen?: Discover the valuable metals inside catalytic converters (such as platinum, palladium, and rhodium) that make them attractive to criminals.
Steps to Prevent Catalytic Converter Theft:
Parking Strategies: Tips on where and how to park your vehicle to reduce the risk of theft, such as parking in well-lit areas or secure garages.
Protective Devices: Overview of various anti-theft devices available, including catalytic converter locks, shields, and alarms.
Etching and Marking: The benefits of etching your vehicle’s VIN on the catalytic converter or using a catalytic converter marking kit to make it traceable and less appealing to thieves.
Surveillance and Monitoring: Recommendations for using security cameras and motion-sensor lights to deter thieves.
Statistics and Insights:
Theft Rates by Borough: Analysis of data to determine which borough in NYC experiences the highest rate of catalytic converter thefts.
Recent Trends: Current trends and patterns in catalytic converter thefts to help you stay aware of emerging hotspots and tactics used by thieves.
Benefits of This Presentation:
Awareness: Increase your awareness about catalytic converter theft and its impact on vehicle owners.
Practical Tips: Gain actionable insights and tips to effectively prevent catalytic converter theft.
Local Insights: Understand the specific risks in different NYC boroughs, helping you take targeted preventive measures.
This presentation aims to equip you with the knowledge and tools needed to protect your vehicle from catalytic converter theft, ensuring you are prepared and proactive in safeguarding your property.
Dahua provides a comprehensive guide on how to install their security camera systems. Learn about the different types of cameras and system components, as well as the installation process.
Charging Fueling & Infrastructure (CFI) Program Resources by Cat PleinForth
Cat Plein, Development & Communications Director of Forth, gave this presentation at the Forth and Electrification Coalition CFI Grant Program - Overview and Technical Assistance webinar on June 12, 2024.
Charging and Fueling Infrastructure Grant: Round 2 by Brandt HertensteinForth
Brandt Hertenstein, Program Manager of the Electrification Coalition gave this presentation at the Forth and Electrification Coalition CFI Grant Program - Overview and Technical Assistance webinar on June 12, 2024.
Expanding Access to Affordable At-Home EV Charging by Vanessa WarheitForth
Vanessa Warheit, Co-Founder of EV Charging for All, gave this presentation at the Forth Addressing The Challenges of Charging at Multi-Family Housing webinar on June 11, 2024.
Welcome to ASP Cranes, your trusted partner for crane solutions in Raipur, Chhattisgarh! With years of experience and a commitment to excellence, we offer a comprehensive range of crane services tailored to meet your lifting and material handling needs.
At ASP Cranes, we understand the importance of reliable and efficient crane operations in various industries, from construction and manufacturing to logistics and infrastructure development. That's why we strive to deliver top-notch solutions that enhance productivity, safety, and cost-effectiveness for our clients.
Our services include:
Crane Rental: Whether you need a crawler crane for heavy lifting or a hydraulic crane for versatile operations, we have a diverse fleet of well-maintained cranes available for rent. Our rental options are flexible and can be customized to suit your project requirements.
Crane Sales: Looking to invest in a crane for your business? We offer a wide selection of new and used cranes from leading manufacturers, ensuring you find the perfect equipment to match your needs and budget.
Crane Maintenance and Repair: To ensure optimal performance and safety, regular maintenance and timely repairs are essential for cranes. Our team of skilled technicians provides comprehensive maintenance and repair services to keep your equipment running smoothly and minimize downtime.
Crane Operator Training: Proper training is crucial for safe and efficient crane operation. We offer specialized training programs conducted by certified instructors to equip operators with the skills and knowledge they need to handle cranes effectively.
Custom Solutions: We understand that every project is unique, which is why we offer custom crane solutions tailored to your specific requirements. Whether you need modifications, attachments, or specialized equipment, we can design and implement solutions that meet your needs.
At ASP Cranes, customer satisfaction is our top priority. We are dedicated to delivering reliable, cost-effective, and innovative crane solutions that exceed expectations. Contact us today to learn more about our services and how we can support your project in Raipur, Chhattisgarh, and beyond. Let ASP Cranes be your trusted partner for all your crane needs!
EV Charging at MFH Properties by Whitaker JamiesonForth
Whitaker Jamieson, Senior Specialist at Forth, gave this presentation at the Forth Addressing The Challenges of Charging at Multi-Family Housing webinar on June 11, 2024.
Charging Fueling & Infrastructure (CFI) Program by Kevin MillerForth
Kevin Miller, Senior Advisor, Business Models of the Joint Office of Energy and Transportation gave this presentation at the Forth and Electrification Coalition CFI Grant Program - Overview and Technical Assistance webinar on June 12, 2024.
Implementing ELDs or Electronic Logging Devices is slowly but surely becoming the norm in fleet management. Why? Well, integrating ELDs and associated connected vehicle solutions like fleet tracking devices lets businesses and their in-house fleet managers reap several benefits. Check out the post below to learn more.
2. Forward–Looking
Statements
This
presenta+on
contains,
and
any
accompanying
oral
presenta+on
would
no
doubt
contain,
forward-‐looking
statements,
within
the
meaning
of
the
Private
Securi+es
Li+ga+on
Reform
Act
of
1995,
regarding
us
(Biocept,
Inc.)
and
our
business.
Forward-‐looking
statements
include
all
statements
that
are
not
historical
facts
and
generally
can
be
iden+fied
by
terms
such
as
an+cipates,
believes,
could,
es+mates,
expects,
intends,
may,
plans,
poten+al,
predicts,
projects,
should,
will,
would,
or
the
nega+ve
of
those
terms
and
similar
expressions.
Forward-‐looking
statements
involve
known
and
unknown
risks,
uncertain+es
and
other
factors
which
may
cause
our
actual
results,
performance
or
achievements
to
be
materially
different
from
any
future
results,
performance
or
achievements
expressed
or
implied
by
the
forward-‐looking
statements.
For
details
about
these
risks,
please
see
our
SEC
filings.
All
forward
looking
statements
contained
in
this
presenta+on
speak
only
as
of
the
date
hereof,
and
except
as
required
by
law,
we
assume
no
obliga+on
to
update
these
forward-‐looking
statements
whether
as
a
result
of
any
new
informa+on,
future
events,
changed
circumstances
or
otherwise.
2
3. Business
Overview
CLIA
facility
in
San
Diego,
CA
Genomic
test
results
sent
to
physicians
R&D
Clinical
Development
CLIA
Lab
R
and
D,
test
kits
manufactured
and
samples
analyzed
Manufacturing
3
4. Investment
Highlights
• OncoCEE™:
measures
circula+ng
tumor
cells
(CTCs)
• OncoCEE-‐BR™
:
first
commercialized
test
for
breast
cancer
• CEE-‐Selector™:
plaorm
expansion
for
muta+on
analysis
• Robust
test
pipeline
focused
on
solid
tumor
genomic
diagnos+cs
including
lung,
breast,
colon,
prostate
and
melanoma
• Established,
cer+fied
and
scalable
CLIA
lab
• Clear
path
to
market
penetra+on
• Established
research
collabora+ons
and
strategic
partnerships
• IPO
completed
February
2014;
gross
proceeds
of
$19
million
4
Commercial
stage
cancer
diagnos0cs
company
with
ground-‐breaking
technology
pla9orm
u0lizing
a
simple
blood
test
5. Mul+faceted
Growth
Strategy
• Commercializa+on
– Clinical,
Commercial
– Biopharma
– Partnerships
• Test
Menu
Build
Out
– test
valida+on
– Clinical
u+lity
studies
– Plaorm
expansion
• Opera+onal
Efficiency
– Automa+on
– Process
improvements
– Increase
Gross
Margin
5
6. Biocept
Execu+ve
Team
6
Michael
Nall
President
and
CEO
Lyle
Arnold,
Ph.D.
SVP,
R&D
and
CSO
Farideh
Bischoff,
Ph.D.
VP
TranslaEonal
Research
and
Clinical
Development
Bill
Kachioff
SVP,
Finance
and
CFO
David
Hale
ExecuEve
Chairman
•
More
than
25
years
in
healthcare
sales,
marke+ng
and
commercial
opera+ons
•
14
years
in
cancer
diagnos+cs
and
genomics
•
Most
recently
GM
N.
American
Sales
and
Marke+ng
for
Clarient,
a
GE
Healthcare
Company
•
Senior
R&D
Leadership
at
Gen-‐Probe,
Incyte
Genomics,
Genta
•
Founder/
Co-‐founder
Oasis
Biosciences,
Molecular
Biosystems,
Aegea
Biotechnologies
•
Former
faculty
member,
UCSD
School
of
Medicine
and
member,
UCSD
Cancer
Center
•
39
issued
US
and
140
issued
and
pending
patents
worldwide
•
Former
Associate
Professor
and
member,
Cancer
Center
at
Baylor
College
of
Medicine
•
Postdoc
at
MD
Anderson
and
Baylor
College
of
Medicine
•
More
than
130
peer
reviewed
papers
and
book
chapters
•
Chairman
and
CEO
of
Hale
BioPharma
Ventures
with
over
35
years
as
a
healthcare
visionary
•
Chairman
of
Santarus
(acquired
by
Salix),
Conatus,
Micromet
(acquired
by
Amgen),
and
SkinMedica
(acquired
by
Allergan)
•
CEO
of
Hybritech
(acquired
by
Lilly)
,
Gensia
(acquired
by
Teva)
•
More
than
20
years
life
sciences
experience
•
14
years
of
experience
in
public
company
finance
•
Abboj
Labs,
Cutera,
Coulter
Pharmacue+cal,
Althea,
Vivus
•
Diverse
finance
and
opera+ons
management
experience
Raaj
Trivedi
VP
Commercial
OperaEons
•
More
than
15
years
in
healthcare
sales,
marke+ng
and
business
development
•
Served
as
VP
of
Marke+ng
and
then
VP
of
Business
Development
at
Clarient
•
Life
Technologies
Commercial
Leader
for
Oncomine
Biomarker
Discovery
Plaorms
7. US
Market
Opportunity
7
Cancer
Type
New
Cases/
Year
Living
with
Cancer
Deaths/
Year
Breast 232,340 2,829,041 39,620
Prostate 238,590 2,617,682 29,720
Lung 228,190 399,431 159,480
Colorectal 142,820 1,154,481 50,830
Melanoma 76,690 921,780 9,480
Total 918,630 7,922,415 289,130
*
Incidence,
prevalence
and
deaths
data
provided
by
Na+onal
Cancer
Ins+tute:
hjp://seer.cancer.gov/staacts/
8. Molecular
Cancer
Tes+ng
Market
8
*GEN
Magazine,
Bold
Predic+on
for
Future
Cancer
Tests
*Frost
and
Sullivan
–
Market
Research
2011
**Jain
Pharma
Biotech
June
2011
CAGR
22.9%
for
US
0
0.5
1
1.5
2
2.5
3
2010
2015
2017
N.
America*
Global**
$
Billions
Market
Characteris9cs:
• Increased
reliance
on
molecular
diagnos+cs
for
treatment
decisions
• Expanding
use
of
targeted
therapies
• Greater
sophis+ca+on
of
oncology
diagnos+cs
• Limited
by
need
for
tumor
+ssue
9. Limita+ons
of
Tissue
Biopsy
Cancer
is
a
heterogeneous
disease
– Molecular
proper+es
differ
within
a
tumor
– Primary
tumor
biopsy
may
not
reflect
current
disease
condi+on
– Therapy
causes
changes
in
tumor
cells
Biopsy
is
invasive
– May
not
be
feasible
based
on
pa+ent
condi+on
or
tumor
accessibility
– Imprac+cal
for
periodic
monitoring
for
progression
/
recurrence
Biopsy
+ssue
is
limited
– Greater
demand
due
to
molecular
profiling
– Surgery
is
costly
9
Liquid
Biopsy
Addresses
Limita9ons
in
Standard
of
Care
10. New
Molecular
Paradigm
–
Liquid
Biopsy
• ctDNA
-‐
CTCs
–
Circula+ng
Tumor
Cells,
cell
free
Circula+ng
tumor
DNA
• ctDNA:
demonstrated
surrogate
for
tumor
+ssue
biopsy
• Can
be
captured
and
characterized
for
biomarkers,
similar
to
+ssue
• Liquid
biopsy
repeatable
throughout
treatment,
par+cularly
when
+ssue
unavailable
• 66%
of
researchers
say
analysis
of
CTCs
will
be
standard
of
care
in
the
next
4
years*
10
*CTC
industry
overview
–
Hanson
and
Wade
2013
Solid
tumors
shed
CTCs
and
ctDNA
into
blood
CTCs
and
ctDNA
travel
via
bloodstream
CTCs
&
ctDNA
analyzed
for
pa+ent
treatment
decisions
Breast
cancer
CTC
11. OncoCEE™
Personalized
Genomic
Diagnos+cs
11
Personalized
Treatment
EGFR/ALK/ROS1
K-‐ras
B-‐raf
ZELBORAF®
(vemurafenib)
TARCEVA®
(erlo+nib)
&
IRESSA®
(gefi+nib)
/
XALKORI
®(crizo+nib)
ERBITUX®
(cetuximab)
&
VECTIBIX®
(panitumumab)
HER2
HERCEPTIN®
(trastuzumab
)
The
Right
Therapy
for
the
Right
Pa9ent
at
the
Right
Time
OncoCEE-‐BR™
Breast
Cancer
OncoCEE-‐ME™
Melanoma
OncoCEE-‐CR™
Colorectal
Cancer
OncoCEE-‐LU™
Non-‐small
Cell
Cancer
12. Intellectual
Property
12
CEE-‐SelectorTM
Muta+on
Analysis
Patent
pending
Biocept
Developed
SoluEons
Patented
CEE®
Microfluidic
Channel
CEE-‐Sure™
Stability
Transport
Tube
Patent
pending
OncoCEE™
Chemistry:
An+body
Cocktail
Patent
pending
One
US
and
associated
foreign
patents
pending
Two
issued
US
patents
and
two
issued
foreign
patents;
mulEple
pending
US
and
foreign
patents
Two
US
and
associated
foreign
patents
pending
for
capture;
one
US
and
associated
foreign
patents
pending
for
detecEon
One
US
and
associated
foreign
patents
pending
13. CEE-‐Selector™
Plaorm
• Allows
for
both
CTC
and
cell
free
ctDNA
analysis
• Detects
1
muta+on
out
of
>10,000
normal
DNA
• Works
with
various
nucleic
acid
targets
(DNA
and
RNA)
• Compa+ble
with
sequencing
and
PCR
instruments
• Mul+plexing
reduces
costs
and
enhances
reimbursement
• Poten+al
applica+ons
in
all
stages
of
cancer
13
MutaEon
determinaEon
sensiEvity
10-‐100x
beSer
than
compeEng
plaTorms*
*
Biocept
internal
data
14. 14
OncoCEE-‐BR™
2015
2013
2014
Product
Valida9on-‐
CLIA
Product
Development-‐
R&D
and
TCD
OncoCEE-‐BR™
(DTC)
OncoCEE-‐PR™
OncoCEE-‐LU™
OncoCEE-‐CR™
OncoCEE-‐ME™
Breast
cancer
Bone
marrow
for
breast
cancer
Prostate
cancer
Non-‐small
cell
lung
cancer
Melanoma
Colorectal
cancer
HER2
OncoCEE-‐GA™
Gastric
cancer
Product
Development
Pipeline
Muta9on
FISH
ER
PR
Pre-‐2013
15. 15
OncoCEE™
Product
Profiles
Product
Tumor
Type
OncoCEE™
CTC
CEE-‐Selector™
OncoCEE-‐BRTM
(launched)
Breast
Enumera+on
of
CTCs
,
HER2,
ER,
PR
Currently
no
clinically
ac+onable
muta+ons
iden+fied
OncoCEE-‐GATM
Gastric
Enumera+on
of
CTCs,
HER2
Currently
no
clinically
ac+onable
muta+ons
iden+fied
OncoCEE-‐LUTM
Lung
Enumera+on
of
CTCs,
ALK,
ROS1
EGFR,
K-‐ras,
B-‐raf
muta+ons
OncoCEE-‐CRTM
Colon
Enumera+on
of
CTCs,
EGFR
K-‐ras,
B-‐raf
muta+ons
OncoCEE-‐PRTM
Prostate
Enumera+on
of
CTCs,
AR,
and
PTEN
dele+on
(blood
or
bone
marrow)
Currently
no
clinically
ac+onable
muta+ons
iden+fied
OncoCEE-‐METM
Melanoma
Enumera+on
of
CTCs
B-‐raf
and
N-‐ras
muta+ons
16. 16
Targeted
Commercializa+on
Strategy
• Raise
awareness
of
the
value
of
ctDNA
• Drive
OncoCEE
adop+on
– Market
directly
to
oncologists
– Develop
key
opinion
leader
speakers
• Build
rela+onships
with
pa+ent
advocacy
groups
• Publish
studies
with
major
cancer
centers
• Par+cipate
in
medical
mee+ngs
/
symposia
• Deepen
payor
rela+onships
and
expand
reimbursement
coverage
• Expand
strategic
partnerships
with
pharma
and
biotech
for
personalized
diagnos+cs
17. 17
Driving
Adop+on
for
Growth
12
Month
Commercial
Team
Build
• Head
of
sales
and
marke+ng
• Regionally
based
sales
team
• Sales
team
for
Pharma
• Managed
care
expert
• Internal
marke+ng
• Leverage
partner
sales
forces
18. 18
Dana-‐Farber
• Metasta+c
Breast
Cancer
pa+ents
with
HER2
nega+ve
primary
biopsy
• CTC
HER2
posi+ve
pa+ents,
as
detected
with
OncoCEE
BR,
placed
on
Hercep+n
•
Sponsored
by
Genentech
•
Results
expected
in
2014014
MD
Anderson
•
Recently
diagnosed
breast
cancer
pa+ents
• 15%
of
CTC
and
28%
of
DTCs
have
HER2
discordance
with
primary
tumor
•
Published
in
Cancer
Medicine
–
April
20132013
Other
studies
• Four
addi+onal
peer
reviewed
published
studies
valida+ng
technology
•
Addi+onal
pending
studies
with
collaborators
•
Planned
study
in
Non
Small
Cell
Lung
Cancer
• Planned
study
in
Non
Small
Cell
Lung
Cancer
Clinical
U+lity
Studies
19. Investment
Highlights
• OncoCEE™:
measures
circula+ng
tumor
cells
(CTCs)
• OncoCEE-‐BR™
:
first
commercialized
test
for
breast
cancer
• CEE-‐Selector™:
plaorm
expansion
for
muta+on
analysis
• Robust
test
pipeline
focused
on
solid
tumor
genomic
diagnos+cs
including
lung,
breast,
colon,
prostate
and
melanoma
• Established,
cer+fied
and
scalable
CLIA
lab
• Clear
path
to
market
penetra+on
• Established
research
collabora+ons
and
strategic
partnerships
• IPO
completed
February
2014;
gross
proceeds
of
$19
million
19
Commercial
stage
cancer
diagnos0cs
company
with
ground-‐breaking
technology
pla9orm
u0lizing
a
simple
blood
test